Enlivex Earnings Call Transcripts
Fiscal Year 2026
-
A premium-priced transaction with the Rain Foundation aims to strengthen future financing and leverage treasury assets, while Rain protocol milestones show rapid trading growth and ambitious projections. Allocetra's phase I/IIa results in osteoarthritis are promising, with an ongoing phase IIb study and RMAT designation supporting accelerated development.
Fiscal Year 2025
-
2025 saw record net income and EPS, driven by treasury gains from prediction markets, especially RAIN tokens. Clinical progress continued with FDA clearance for a Phase IIb osteoarthritis trial, while new financing and share repurchase initiatives support future growth.
-
Top-line phase II-A data show Allocetra achieved a 72% pain reduction over placebo in primary knee osteoarthritis patients aged 60+, with efficacy increasing in older groups and a favorable safety profile. The company plans a phase II-B trial, is initiating partnership discussions, and expects its competitive pricing to support broad adoption.